SCHEMBL1420186

SCHEMBL1420186

O=C(Nc1cccc(C(F)(F)F)c1)c1cc(F)cc(N2CCC(N3CCCC3)CC2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPY2R P49146 1/20 0.51
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
MAPT P10636 6/20 0.49
FGFR1 P11362 1/20 0.48
DDR2 Q16832 1/20 0.48
TRPV4 Q9HBA0 1/20 0.47
RXFP1 Q9HBX9 4/20 0.47
ALDH1A1 P00352 3/20 0.47
LMNA P02545 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.46
UBE2M P61081 1/20 0.46
DCUN1D1 Q96GG9 1/20 0.46
RAB9A P51151 2/20 0.46
NPC1 O15118 1/20 0.46
TP53 P04637 1/20 0.46
TSHR P16473 1/20 0.46
L3MBTL3 Q96JM7 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
CCR2 P41597 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1420819 0.92 NPY2R (0.53) NPY2RMEN1KMT2AMAPTFGFR1
SCHEMBL1420450 0.91 NPY2R (0.54) NPY2RMEN1KMT2AMAPTFGFR1
SCHEMBL1420138 0.89 MAPT (0.58) NPY2RMEN1KMT2AMAPTFGFR1
SCHEMBL1420508 0.89 P2RX1 (0.51) NPY2RMEN1KMT2AMAPTLMNA
SCHEMBL1420032 0.86 NPY2R (0.51) NPY2RMEN1KMT2AMAPTRXFP1
SCHEMBL1420090 0.85 CSF1R (0.45) NPY2RTRPV4L3MBTL3L3MBTL1KDR
SCHEMBL1420034 0.85 SMN1; SMN2 (0.56) NPY2RMEN1KMT2AMAPTDDR2
SCHEMBL1420274 0.84 P2RX1 (0.59) NPY2RMAPTRXFP1ALDH1A1LMNA
SCHEMBL1420117 0.84 LMNA (0.49) NPY2RMAPTTRPV4RXFP1LMNA
SCHEMBL1962805 0.84 FGFR1 (0.58) FGFR1DDR2RXFP1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2011524365-A 2011-09-01 JP claimed
US-20110144107-A1 COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA IRM LLC (BM) 2011-06-16 US claimed
EP-2297097-A2 COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA IRM LLC (BM) 2011-03-23 EP claimed
WO-2009152356-A2 COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA IRM LLC (BM) 2009-12-17 WO claimed
US-20110144107-A1 COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA IRM LLC (BM) 2011-06-16 US disclosed
US-20110144107-A1 COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA IRM LLC (BM) 2011-06-16 US disclosed
EP-2297097-A2 COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA IRM LLC (BM) 2011-03-23 EP disclosed
WO-2009152356-A2 COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA IRM LLC (BM) 2009-12-17 WO disclosed
WO-2009152356-A2 COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA IRM LLC (BM) 2009-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144107-A1 COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA G6PD, DHFR, SGMS1 NPY2R 4064/4885MEN1 837/4885KMT2A 3409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.